Natures way to help prevent/treat AD from Brest milk:



Alzheimer's Disease

"New understandings in the treatment of AD"

Due to the failure of drugs having any significant impact on the condition, research into the treatment for Alzheimer's has been redirected to discovering possible treatments using colostrum extracts. ReGen Therapeutics has played a major role in this development and now is in the position after many years of research to release a product onto the market place which has been trademarked under the name of Colostrinin™. It has been under development as a neutraceutical treatment for 'the prevention of cognitive decline' in both humans and animals. In particular, diseases such as such as Alzheimer's and possibly the treatment of Parkinson's Disease.

From a general terminology point of view, Colostrinin is a proline-rich polypeptide complex produced from colostrum (a mammal's first milk) and is being developed as a nutraceutical for use in humans and animals for the prevention of early stage cognitive decline and is in advanced development as a treatment for Alzheimer's disease. Current research has been promising with Colostrinin™ showing efficacy in a 106 patient, placebo controlled trial conducted in mild/moderate Alzheimer's sufferers over 30 weeks. Results announced in April 2005 indicate that peptides within Colostrinin may have potential as a therapy for Parkinson's disease as well.

Colostrinin™ is ReGen's lead compound, which as mentioned is a proline-rich polypeptide complex produced from colostrum (a mammals' first milk after birth). In in vitro studies Colostrinin™ has been shown to prevent the aggregation of beta-amyloid and reduce it’s toxicity to cells. Beta-amyloid is the toxic peptide that is the main constituent of the characteristic plaques’ that form in the brains of people with Alzheimer’s disease and cause loss of cognitive function. Colostrinin™ has also been shown to protect cells from oxidative stress another of the pathologies implicated in Alzheimer’s disease. In in vivo studies Colostrinin™ has been shown to improve memory performance of aged rats in the Morris water maze test. Colostrinin has shown efficacy in a 106 patient, placebo controlled trial conducted in mild/moderate Alzheimer's sufferers over 30 weeks. Furthermore, Colostrinin™ and a synthetic homologue of Colostrinin™-derived peptide show neuroprotection in a cell line model of Parkinson's disease. An in vitro study has shown that pre-treatment with Colostrinin™ and a synthetic version of a peptide shown to occur naturally in Colostrinin™ can protect cells of the kind that are depleted in Parkinson's disease from damage by a chemical known to be selectively toxic to them. The initial data from this study suggests that Colostrinin™ and peptides within it may protect dopaminergic neurones against degeneration.

An in vitro study has shown that Colostrinin™ can cause precursor nerve cells to differentiate and proliferate. These findings suggest that Colostrinin™ treatment may control the expression of genes that are involved in the development, maintenance, and regeneration of neurons in the central nervous system, and thus may also explain the improvements observed in Alzheimer's patients with mild-to-moderate dementia during treatment with Colostrinin™.

A further in vitro study has shown that Colostrinin™ increases the lifespan of cells isolated from inbred mice predisposed to premature ageing and therefore, death. This study shows the impact of Colostrinin™ on the mitochondria of cells isolated from strains of senescence-prone (SAMP1) and senescence-resistant (SAMR1) mice. The data show that cells from SAMP1 mice produce more ROS, exhibit severe mitochondrial dysfunction, and have a decreased lifespan compared to the cells from SAMR1 mice. Addition of Colostrinin™ to SAMP1 cells significantly decreased ROS levels, normalized mitochondrial function and increased the lifespan to levels similar to those in SAMR1 cells. This is an exciting finding that may go toward explaining the cognitive benefits of Colostrinin™ seen in clinical studies. In vivo experiments are now ongoing to test if these effects are evident when SAMP1 and SAMR1 mice are given Colostrinin™ over their lifetime.

Having now achieved the production of Colostrinin™ at industrial scale ReGen announces that it is starting formal safety studies with Colostrinin™. While there have been no safety concerns associated with the use of Colostrinin™ in previously conducted safety or clinical studies, this is a key milestone for ReGen as these earlier studies used Colostrinin™ made with a small-scale process and using ovine rather than bovine colostrum. In parallel with the safety program, work continues to complete the incorporation of Good Manufacturing Practise (GMP) into the production process.

Last September ReGen presented preliminary evidence of an anti-ageing effect from Colostrinin™ at the 21st International Conference of Alzheimers Disease International taking place in Istanbul. Researchers saw that the product increased the lifespan of cells isolated from mice predisposed to premature ageing and therefore, death, when they tested its impact on the mitochondria of cells isolated from strains of senescence-prone (SAMP1) and senescence-resistant (SAMR1) mice.

While cells from SAMP1 mice produce more reactive oxygen species (ROS), exhibit severe mitochondrial dysfunction, and have a decreased lifespan compared to the cells from SAMR1 mice, adding Colostrinin significantly decreased ROS levels, normalized mitochondrial function and increased the lifespan to levels similar to those in SAMR1 cells.

Continuous low levels of oxidative damage to cells, caused by ROS, play a key role in age-associated neurodegenerative diseases such as Alzheimer's, Parkinson's disease and other disorders of the central nervous system.

Conclusion:

Based on current research, Colostrinin has the potential as a treatment for Alzheimer’s disease, Parkinson's disease and other neurodegenerative disease conditions.

Very Interesting. I will keep following any progress. Let us know how the results are on Alheimer's patients!

Felicia

Hi Felicia

You may be interested to know that Colostrinin has shown to work in AD for Pets too, as this news clip shows from only last month.

Kind regards, Rosie


-----------------------------------------------
Colostrinin™ Study Results

11/02/2008

ReGen Therapeutics Plc ('ReGen'or the 'Company') announces that its product Colostrinin™, which is currently marketed in the USA and Australia under the brand name CogniSure™, a nutritional supplement to 'support healthy brain aging and cognition in humans'* has recently been shown to be beneficial and well-tolerated in aging pet cats and dogs with signs of senility and/or cognitive dysfunction.

Open pilot studies, conducted by Cinque Ports Veterinary Associates, Hawkhurst, Kent, UK involved the daily dosing of aged cats and dogs with Colostrinin™ powder sprinkled into their food or drink.

To be eligible for the study, subject animals displayed acknowledged clinical signs of senility and/or cognitive dysfunction. Eighteen cats and twenty-two dogs, each resident in their normal domestic environment, received a daily dose of Colostrinin™ for four months. The clinical condition of each animal was assessed by a veterinary surgeon and the owner completed a questionnaire about aspects of the animal's behaviour at monthly intervals. Results were compared to individual base-line assessments, prior to treatment.

Summarising the study findings Nicholas Mills, Principal Investigator to the study said 'These results clearly show that Colostrinin™ can significantly reduce the symptoms of cognitive dysfunction in aged cats and dogs. That Colostrinin™ was effective was reinforced by the fact that when animals were assessed one month after completion of the study, and having had no Colostrinin™ for one month, most animals showed a worsened condition'.

The study showed Colostrinin™ to be well tolerated. With regard to specific benefits, a number of owners noted improvements in symptoms related to disorientation, sleep and grooming. A significant proportion of owners reported an increase in appetite, water consumption and an improvement in coat condition.

Percy Lomax, Chairman and Chief Executive Officer of ReGen said 'These results show a potential benefit for aging cats and dogs and we are entering into discussions with potential licensees. The full results are being written up with a view to publication in a peer-eviewed veterinary journal'.

More Colostrinin news announced today :



Results of Study

31/03/2008

In-vivo study shows ReGen's ColostrininTM to be non-allergenic and able to prevent allergic inflammation.


ReGen Therapeutics Plc ('ReGen') is pleased to announce a report of a study conducted by Dr Istvan Boldogh* of the University of Texas Medical Branch was published on the 27 March on line in the International Archives of Allergy and Immunology. This study shows that ColostrininTM , ReGen's nutraceutical product, being marketed by Metagenics Inc., California for the 'support of healthy brain ageing and cognition', is not only non-allergenic, but prevents allergic inflammation due to common indoor and outdoor allergens.

Currently Metagenics and or its subsidiaries are selling ColostrininTM in Australasia since July 2007 and North America since October 2007. Headquartered in San Clemente, California, Metagenics is a leading developer, manufacturer and marketer of nutraceuticals, dedicated to researching and evaluating the effects of natural ingredients on genetic expression and protein activity. Additionally, on 25 March 2008 ReGen announced its first approval to launch in the European Union in Cyprus through Golgi Pharmaceuticals Ltd its distributor for that market.

Highlights of the study are as follows:


The objective of the study was to investigate potential allergic responses to ColostrininTM and its impact on allergic sensitisation and inflammation caused by common allergens to underpin its safe use as a human nutraceutical . A spray-dried whole Colostrum product which is commercially available as a nutraceutical was used as a control
The study used a well characterised mouse model of allergic airway inflammation
ColostrininTM (given orally, intranasally or intraperitoneally) significantly decreased IgE/IgG1 production, airway eosinophilia, mucin production and hypersensitivity induced by allergenic extracts from ragweed pollen and house dust mites
In contrast, Colostrum, from which ColostrininTM is derived, induced positive inflammatory responses
Commenting on these findings Dr. Marian Kruzel (a co-author of the publication and a scientific advisor to ReGen) said: ' These findings are entirely consistent with Colostrinin'sTM safety profile and use to support healthy cognition through significant reduction of reactive oxygen species (ROS) build up.'

Percy Lomax, Chairman and Chief Executive Officer added: 'The data shows that ColostrininTM may be used in humans without concern about experiencing an allergic reaction. This is in contrast to other less refined dairy-derived products, in particular whole colostrum, which is a significant US dietary product. We believe these findings will give impetus to the marketing of ColostrininTM.

i new to this chat stuff and just placed a treatment statement elsewhere. i looking for reference to methylcobalimen (methly b12) and phopholipids as a means to slow down and repair brain cells. this ring a bell with anyone? the colostrinin sounds very interesting indeed! anyone taking the chinese or ayurvedic medicine approaches? jbell

John ...

Google: methylcobalamin phospholipid neuron repair

You'll get 1,100 hits.

If you don't mind wading through a lot of jargon, I typically use Google Scholar to look for things medical, research, etc. You will get a narrower search of the scientific and patent literature. I got 69 hits for the same search here.

To use Google Scholar, go to:

http://scholar.google.com

and then search as you would on Google itself. You will see that each "hit" will say, in paler blue, "all 2 versions" or "all 5 versions" etc. These are mutliple hits for the same paper. Sometimes you can locate free .pdf downloads of the paper by clicking on the different "versions". Others will take you to sites that give you just the abstract, but that can help you decide whether you want to track down the paper.